ClinicalTrials.gg
RecruitingNCT07644364Updated Jul 22, 2026

HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With Hypertension

A Phase 1 interventional study of HJB647 and Placebo in Elevated Blood Pressure and Hypertension, sponsored by Novartis Pharmaceuticals. Recruiting at 1 site in Japan. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-07-22.

Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2026; still recruiting 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 227 studies in Hypertension by Novartis — 4 open to participants now, 5 under way, none of them phase 3. Hypertension · Novartis.

Planned enrollment
180th of 222
64 · median 309
Started
2026
with 3 others
Phase 1
17 of 227
1 open now
Registered
227th of 227
by date

Among the 227 studies in Hypertension by Novartis, this one is the 180th largest by planned enrollment of the 222 interventional ones that give a count, is one of 4 that started in 2026, is one of 17 in phase 1, and was the 227th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

4 of the 227 studies in Hypertension by Novartis are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 227 studies in Hypertension by Novartis, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacokinetics, and pharmacodynamics of HJB647 following single dose administration in Japanese healthy participants with elevated blood pressure and multiple dose administration with up titration in Japanese patients with hypertension, to support future clinical development of HJB647

Read the detailed description

Randomized, placebo-controlled, participant- and investigator-blind study consisting of two parts:

  • Part 1 (SAD part): Single oral dose in healthy participants. Sentinel dosing will be applied in each cohort.
  • Part 2 (MAD part): Multiple oral doses in patients with hypertension. Safety reviews will guide dose escalation and up-titration.
03

Conditions studied

  • Elevated Blood Pressure
  • Hypertension

Browse trials for

Keywords

  • HJB647
  • safety
  • tolerability
  • pharmacokinetics
  • Japanese participants with elevated blood pressure
  • Japanese patients with hypertension
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese healthy participants with elevated blood pressure (Part 1) and patients with mild-to-moderate hypertension (Part 2)
  • Age: 18 to 55 years (Part 1) and 18 to 60 years (Part 2)
  • Body weight:

    • Male: ≥ 50.0 kg
    • Female: ≥ 45.0 kg
  • (BMI): 18.0 to 30.0 kg/m²
  • Axillary body temperature: 35.0-37.5 °C
  • Heart rate: 50-90 bpm
  • Blood pressure criteria are as follows:

    • Part 1: Healthy Participants with Elevated Blood Pressure Screening: Systolic Blood Pressure (SBP): 120 ≤ SBP ≤ 139 mmHg; Diastolic Blood Pressure (DBP): 60 ≤ DBP ≤ 94 mmHg Baseline (Day -1): SBP: 120 ≤ SBP ≤ 179 mmHg; DBP: 60 ≤ DBP ≤ 109 mmHg
    • Part 2: Patients with Hypertension Screening and Baseline (Day -1): SBP: 140 ≤ SBP ≤ 179 mmHg; DBP: 60 ≤ DBP ≤ 109 mmHg

Exclusion criteria

Exclusion Criteria:

  • Significant illness, including infectious diseases that have not resolved within 30 days prior to baseline
  • History or current diagnosis of or cardiac abnormalities indicating significant risk of safety for participants such as:

    • Concomitant cardiac arrhythmias, e.g., sustained ventricular tachycardia, and clinically significant second- or third-degree AV block without a pacemaker.
    • History of familial long syndrome or known family history of Torsades de Pointes
    • Resting QT interval corrected by Fridericia's formula (QTcF) ≥ 450 msec (male) or ≥ 460 msec (female) at screening
  • At screening, hypokalemia or hypomagnesemia defined as potassium or magnesium values below the LLN on repeat measurement, or laboratory abnormalities indicating hypothyroidism, as determined at the discretion of the investigator
  • ≥ 7.0% or LDL cholesterol ≥ 180 mg/dL or triglycerides ≥ 250 mg/dL
  • Use of any prescription drugs or herbal supplements within 4 weeks prior to initial dosing, and/or OTC medication or dietary supplements (vitamins included) within 2 weeks prior to initial dosing
  • Women of

Other protocol-defined inclusion/exclusion criteria may apply

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Part 1-1: HJB647 low dose

    Single dose Day 1 in Part 1

    Drug: HJB647

  • Experimental
    Part 1-2: HJB647 mid-dose

    Single dose Day 1 in Part 1

    Drug: HJB647

  • Experimental
    Part 1-3: HJB647 high dose

    Single dose Day 1 in Part 1

    Drug: HJB647

  • Placebo comparator
    Part 1: Placebo

    Single dose Day 1 in Part 1

    Drug: Placebo

  • Experimental
    Part 2-1: HJB647 multiple oral doses

    Multiple oral doses of HJB647 with adaptive up-titration in Part 2

    Drug: HJB647

  • Experimental
    Part 2-2: HJB647 multiple oral doses (optional cohort)

    Multiple oral doses of HJB647 with adaptive up-titration in Part 2

    Drug: HJB647

  • Experimental
    Part 2-3: HJB647 multiple oral doses (optional cohort)

    Multiple oral doses of HJB647 with adaptive up-titration in Part 2

    Drug: HJB647

  • Experimental
    Part 2-4: HJB647 multiple oral doses (optional cohort)

    Multiple oral doses of HJB647 with adaptive up-titration in Part 2

    Drug: HJB647

  • Experimental
    Part 2-5: HJB647 multiple oral doses (optional cohort)

    Multiple oral doses of HJB647 with adaptive up-titration in Part 2

    Drug: HJB647

  • Placebo comparator
    Part 2: Placebo

    Multiple oral doses of placebo with adaptive up-titration in Part 2

    Drug: Placebo

Interventions

  • DrugHJB647

    HJB647 oral capsule

  • DrugPlacebo

    Matching oral placebo

06

What researchers measure

Primary outcomes

  1. Part 1: Cmax

    Cmax: The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)

    Time frame: Part 1 on Day 1

  2. Part 1: Tmax

    Tmax: The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)

    Time frame: Part 1 on Day 1

  3. Part 1: AUClast

    AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)

    Time frame: Part 1 on Day 1

  4. Part 1: AUCinf

    AUCinf: The AUC from time zero to infinity (mass x time x volume-1)

    Time frame: Part 1 on Day 1

  5. Part 1: T1/2

    T1/2: The elimination half-life associated with the terminal slope (λz) of a semi logarithmic concentration-time curve (time). Use qualifier for other half-lives

    Time frame: Part 1 on Day 1

  6. Part 2: Number of participants with AEs

    Number of participants with adverse events (AEs) including abnormal vital signs, ECG, and safety laboratory parameters

    Time frame: Up to 51 days

Secondary outcomes

  1. Part 1: Number of participants with AEs

    Number of participants with adverse events (AEs) including abnormal vital signs, ECG, and safety laboratory parameters

    Time frame: Up to 31 days

  2. Part 2: Cmax

    Cmax: The maximum (peak) observed plasma, blood, serum, or other body fluid drug concentration after single dose administration (mass x volume-1)

    Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21

  3. Part 2: Tmax

    Tmax: The time to reach maximum (peak) plasma, blood, serum, or other body fluid drug concentration after single dose administration (time)

    Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21

  4. Part 2: AUClast

    AUClast: The AUC from time zero to the last measurable concentration sampling time (tlast) (mass x time x volume-1)

    Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21

  5. Part 2: AUCinf

    AUCinf: The AUC from time zero to infinity (mass x time x volume-1)

    Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21

  6. Part 2: AUCtau

    AUCtau: The AUC calculated to the end of a dosing interval (tau) at steady-state (amount x time x volume-1)

    Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21

  7. Part 2: T1/2

    T1/2: The elimination half-life associated with the terminal slope (λz) of a semi logarithmic concentration-time curve (time). Use qualifier for other half-lives

    Time frame: Part 2 Day 1, Day 7, Day 8, Day 14, Day 15 and Day 21

  8. Part 2: Office blood pressure change from baseline

    Change in office blood pressure from baseline

    Time frame: Baseline to Day 27 of part 2

  9. Part 2: Heart rate change from baseline

    Change in heart rate from baseline

    Time frame: Baseline to Day 27 of part 2

07

Study locations

1 of 1 sites recruiting
  • Novartis Investigative Site
    Sumida Ku, Tokyo 1300004, Japan
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2026 (actual). Primary completion is estimated for Dec 2026, 5 months after the start.

Of 132 industry-sponsored phase 1 interventional studies under Hypertension, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's planned 5 months is above that.

Counting every sponsor, half of 176 studies reached it within 4 months; a quarter within 1 and three quarters within 18.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 8, 2026
First posted
Jun 12, 2026
StartActual
Jul 2, 2026
Primary completionEst.
Dec 25, 2026
CompletionEst.
Dec 25, 2026
Last update
Jul 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07644364
Responsible party
Sponsor
First posted
Jun 12, 2026
Start date
Jul 2, 2026
Primary completion
Dec 25, 2026 (estimated)
Completion
Dec 25, 2026 (estimated)
Last update
Jul 22, 2026

Study contacts

Novartis Pharmaceuticals
Contact
novartis.email@novartis.com
+81337978748
Novartis Pharmaceuticals
Contact
Novartis Pharmaceuticals
study director · Novartis Pharmaceuticals

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion